Stavropoulos-Giokas Catherine, Dinou Amalia, Papassavas Andreas
Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), 4 Soranou Efessiou Street, 115 27 Athens, Greece.
Bone Marrow Res. 2012;2012:485160. doi: 10.1155/2012/485160. Epub 2012 Oct 11.
In recent years, umbilical cord blood (CB), a rich source of hematopoietic stem cells (HSC), has been used successfully as an alternative HSC source to treat a variety of hematologic, immunologic, genetic, and oncologic disorders. CB has several advantages, including prompt availability of the transplant, decrease of graft versus host disease (GVHD) and better long-term immune recovery, resulting in a similar long-term survival. Studies have shown that some degree of HLA mismatches is acceptable. This review is intended to outline the main aspects of HLA matching in different settings (related, pediatric, adult, or double-unit HSCT), its effect on transplantation outcome and the role of HLA in donor selection.
近年来，脐带血（CB）作为造血干细胞（HSC）的丰富来源，已成功用作替代HSC来源，用于治疗各种血液学、免疫学、遗传学和肿瘤学疾病。脐带血有几个优点，包括移植可迅速获得、移植物抗宿主病（GVHD）减少以及长期免疫恢复更好，从而带来相似的长期生存率。研究表明，一定程度的HLA不匹配是可以接受的。本综述旨在概述不同情况下（亲属、儿科、成人或双单位造血干细胞移植）HLA配型的主要方面、其对移植结果的影响以及HLA在供体选择中的作用。
